MediNice SA · GPW:ICE
MediNice SA — Investor Presentation (2025)
22 slides from MediNice SA's investor presentation, Nov 13, 2025

Slide 1: Advancing Patients’ Care
1 Advancing Patients’ Care PacePress | CoolCryo | MiniMax | AtriClamp Corporate presentation 2025 © 2025 Medinice S.A. All rights reserved. © 2025 Medinice S.A. All rights reserved. © 2025 Medinice s.a. All rights reserved.

Slide 2: Forward Looking Statement and Legal Notice
2 FORWARD LOOKING STATEMENT We develop advanced solutions to support patients with cardiovascular diseases LEGAL NOTICE This document has been prepared for information purposes only. It does not constitute an advertisement or offer of securities in public trading. It uses sources of information that

Slide 3: Company Overview: Who We Are
3 COMPANY OVERWIEV WHO WE ARE Established in 2012 by renowned medical professionals and seasoned entrepreneur. Innovates, develops, and commercializes advanced cardiovascular care technologies. Listed on the Warsaw Stock Exchange since 2018. Holds ISO 13485 and CE MDR for PacePress. The 510(k) pathw

Slide 4: Leadership Team
4 LEADERSHIP TEAM Piotr Suwalski Sanjeev Choudhary MD PhD Prof CEO & CO-FOUNDER CO-FOUNDER CO-INVENTOR Graduate of Wroclaw University of Technology, Ashridge Business School, First LAAO in 2009 in Poland. The only MBA, INSEAD and Centre for Creative surgeon in Europe with 500+ robotic Leadership pro

Slide 5: Scientific Board
5 SCIENTIFIC BOARD CARDIAC SURGERY ELECTRO PHISIOLOGY Piotr Valavanur Paul Paweł Michael Adam Suwalski Subramanian Gründeman Balsam Glikson Budzikowski MD, PhD, Prof MD, PhD MD, PhD MD, PhD, Prof MD, PhD, Prof MD, PhD Director of National Head of Lenox Hill Former Director Head of Clinical Director

Slide 6: Pipeline of wide range innovative medical devices
6 PROJECT PORTFOLIO Pipeline of wide range innovative medical devices AtriClamp MiniMax ® CoolCryo ® PacePress ® epicardial RF ablation catheter quick & powerful prevention of LAAO device offering 3D mapping epi- & endocardial hematoma after and cooling cryoablation CIED implants PROTOTYPING PRECLIN

Slide 7: PacePress
7 ADVANCED WOUND CARE PacePress ® © 2025 Medinice S.A. All rights reserved.

Slide 8: PacePress: Safer and faster recovery after CIED implantations
8 PACEPRESS ® Safer and faster recovery after implantations of Cardiac Implantable Electronic Devices PacePress is pneumatic therapeutic medical device designed to minimize the risk of complications after CIED implantations, while ensuring patient comfort, mobility and recovery. Key features • Reduc

Slide 9: CIED Postoperative Complications
9 CIED POSTOPERATIVE COMPLICATIONS 1.5 million procedures performed annually worldwide About 60% of patients undergoing CIED implantation procedures are at risk of postoperative complications. Approximately 10% of CIED procedures result in CIED chest cavity haematomas, potentially leading to implant

Slide 10: CoolCryo
10 CRYOABLATION CoolCryo ® © 2025 Medinice S.A. All rights reserved.

Slide 11: CoolCryo: Faster and more efficient cardiac cryoablation system
11 COOLCRYO ® Faster and more efficient cardiac cryoablation system The CoolCryo® system is designed for the cryosurgical treatment of arrhythmic cardiac tissue ablation by freezing target tissues, inducing an inflammatory response (cryonecrosis) that blocks the electrical conduction pathway. Using

Slide 12: Cardiovascular Diseases: arrhythmia
12 CARDIOVASCULAR DISEASES 59 mln people worldwide suffer from arrhythmia Arrhythmia ranks among the most prevalent heart conditions. It can result in circulatory failure and strokes. The preferred treatment approach is ablation. Currently, ablation treatments include: •Cryoablation (CoolCryo®) – fr

Slide 13: MiniMax
13 RF ABLATION MiniMax ® © 2025 Medinice S.A. All rights reserved.

Slide 14: MiniMax: Versatile RF ablation catheter
14 MINIMAX ® Versatile RF ablation catheter offering 3D mapping and cooling MiniMax® is a steerable, minimally invasive 2-in-1 catheter developed for the treatment of cardiac arrhythmias during RF ablation procedure. It combines ablation and 3D mapping functions to reduce both the risk and duration

Slide 15: AtriClamp
15 LEFT ATRIAL APPENDAGE MANAGEMENT AtriClamp © 2025 Medinice S.A. All rights reserved.

Slide 16: AtriClamp: Scalable Left Atrial Appendage Closure system
16 ATRICLAMP Scalable Left Atrial Appendage Closure system AtriClamp is a cardiothoracic clamp designed for the LAAC procedure. Utilizing an epicardial approach, it eliminates the need for threading through the appendage, keeping blood clots sealed within the appendage. Key features: • low-cost and

Slide 17: Stroke Prevention
17 STROKE PREVENTION 15 million people affected annually According to the World Health Organization, stroke is a leading cause of death, accounting for 11% of all deaths worldwide[1,2]. The left atrial appendage closure procedure prevents 90% of embolic material, leading to 87% of strokes. This proc

Slide 18: Summary
18 SUMMARY Repeatable revenue model Growing demand An experienced team • Growing demand for minimally • Scientific Council composed of world-renowned invasive technologies scientists and inventors • Ageing population • Experienced management and project teams Competitive advantages Large and healthy

Slide 19: Thank you for your attention
19 Thank you for your attention www.medinice.eu © 2025 Medinice S.A. All rights reserved.

Slide 20: Appendix
20 APPENDIX Medinice ® APPENDIX In response to the needs of doctors, we break the boundaries of technological innovation. To ensure the quality of life of patients, we create minimally invasive and safe medical devices. © 2025 Medinice S.A. All rights reserved.

Slide 21: Cardiac Market
21 CARDIAC MARKET Advancing through the development process enhances the product’s value LAAO market 300 mln USD 250 K procedures annually AtriClamp acquisition of SentreHEART $1.9 B market size by AtriCure in 2019 RF Ablation market 125 mln USD 1.5 M procedures annually MiniMax ® w 2023 MACOM acqui

Slide 22: 510k Review Procedure After Submission of the Application
22 SCHEDULE OF THE PROCESS 510k Review – Procedure After Submission of the Application Day Day Day Day Day 1 7 15 60 90 Submission Acknowledgement Letter Acceptance Review Substantive Review Decision Letter The FDA The FDA sends a The lead reviewer checks The application undergoes The FDA informs ab
Source: Internet Archive copy of medinice.pl


